MII is a partnership between the state of Maryland and five of the state’s academic research institutions to promote the commercialization of research and is operated by TEDCO. The program fosters the transition of technologies having significant commercial potential from participating universities, including The Johns Hopkins University, to the commercial sector by funding technology validation, market assessment and the creation of start-up companies in Maryland.
Sonoval LLC and Renalert LLC will both receive Company Formation awards of $150,000 each. Sonoval is developing a breakthrough anti-cancer biologic drug therapy for the treatment of a variety of T cell lymphomas and major solid tumors.
Renalert is developing the Renalert System to provide early detection of the onset of acute kidney injury through novel analysis of a patient’s urine output, blood pressure and oxygenation status.
Author: Johns Hopkins Technology Ventures
Read full article